Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA)
Go back to Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA)| (NASDAQ: JAGX) | Delayed: 2.69 -0.13 (4.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.82 | 52 Week High | $4.60 | |||
| Open | $2.84 | 52 Week Low | $0.81 | |||
| Day High | $2.90 | P/E | N/A | |||
| Day Low | $2.61 | EPS | $0.00 | |||
| Volume | 56,661 | |||||
